Asia Fresh News

Asia Fresh Stories

Archive for April 8th, 2015

Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI(R) (crizotinib)

leave a comment »

DARMSTADT, Germany and NEW YORK /PRNewswire/ —

Not intended for UK-based media

  • In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and theUnited Kingdom)
  • In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck
  • Co-promotion of XALKORI allows the Merck-Pfizer alliance to establish a combined oncology sales organization in key markets for the program

Merck and Pfizer today announced the finalization of the co-promotion agreement allowing the companies to jointly co-promote Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib). This agreement showcases the alliance’s commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab*-based treatment regimens in the future.

XALKORI is the first ALK inhibitor approved in the United States, Japan and the European Union (EU) and is supported by two positive global randomized trials in the first- and second-line ALK-positive advanced non-small cell lung cancer (NSCLC) treatment settings. To date, globally more than 8,000 patients have been treated with XALKORI, including those who received XALKORI in clinical trials.

Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries (France, Germany,Italy, Spain and the United Kingdom). In the United States and Canada, XALKORI will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck. The second wave will begin in 2016 and includes China and Turkey.

In 2015, Merck will receive a reimbursement associated with its promotion of XALKORI, followed by an 80 percent (Pfizer), 20 percent (Merck) profit sharing on the product starting in 2016. The co-promotion term will last throughDecember 31, 2020 for the United States, Canada, Japan, France, Germany, Italy, Spain and the United Kingdomand from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck.

“We are proud and excited to share the legacy of XALKORI, a medicine that changed the treatment paradigm for patients with ALK-positive metastatic NSCLC, with Merck,” said Liz Barrett, President and General Manager, Pfizer Oncology. “Through our co-promotion of XALKORI, we will establish a best-in-class global sales organization that will be exceptionally prepared for the potential launches of our future oncology medicines.”

“As we progress our robust program to co-develop and co-commercialize avelumab, the co-promotion agreement is an exciting milestone for the alliance between Merck and Pfizer, allowing us to establish our combined oncology sales organization in key markets for the program,” said Dr. Andrew Schiermeier, General Manager for the Merck-Pfizer Alliance and Head of Global Oncology, adding: “For Merck, this agreement is particularly important as it accelerates the establishment of our United States and Canada oncology sales organization ahead of our potential avelumab launches and positions us for future success in this market.”

This co-promotion relationship is related to the announcement in November 2014 of a global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab, an investigational anti-PD-L1 monoclonal antibody, to accelerate the development of immuno-oncology medicines for patients with cancer. The immuno-oncology alliance will also advance Pfizer’s PD-1 antibody.

*Avelumab is the proposed International Nonproprietary Name (INN) for the anti-PD-L1 monoclonal antibody (MSB0010718C)

About Non-small Cell Lung Cancer

Globally, lung cancer is the most common cause of cancer-related deaths in men and the second most common in women, responsible for almost twice as many deaths as both breast and prostate cancer combined[1]. Non-small cell lung cancer is the most common type of lung cancer, accounting for 85 to 90 percent of all lung cancers[2]. Locally advanced and metastatic disease account for approximately 35 to 40 percent[3 and 70 percent[4 of patients, respectively with NSCLC.

About XALKORI® (crizotinib)

XALKORI is a kinase inhibitor indicated in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The US indication is not limited to any specific line of therapy. In the EU, XALKORI is indicated for the treatment of adults with previously treated ALK-positive advanced NSCLC. XALKORI has received approval in more than 80 countries.  For more information and full prescribing information, please see:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002489/WC500134759.pdf.

Merck-Pfizer Alliance

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck.  The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The companies will collaborate on up to 20 high priority immuno-oncology clinical development programs, including combination trials, many of which are expected to commence in 2015.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at http://www.pfizer.com.

Merck

Merck of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck holds the global rights to the Merck name and brand. The only exceptions areCanada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Pfizer Disclosure Notice

The information contained in this release is as of April 7, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an agreement between Pfizer and Merck to co-promote Pfizer’s XALKORI in certain markets as well as about the companies’ immuno-oncology alliance involving avelumab and Pfizer’s anti-PD-1 antibody and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the success of the co-promotion arrangement and whether the companies will realize the anticipated benefits of the co-promotion arrangement; the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results; risks associated with interim data, including the risk that the final results of the Phase I study for avelumab and/or additional clinical trials may be different from (including less favorable than) the interim data results and may not support further clinical development; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential product candidates or combination therapies; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of any of such product candidates or combination therapies; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at http://www.sec.gov andhttp://www.pfizer.com.

References

  1. American Cancer Society. (2011). Global Facts & Figures Second Edition.  Retrieved from:http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
  2. American Cancer Society. (2014). Lung Cancer (Non-Small Cell) [Fact sheet]. Retrieved from:http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf
  3. Blumenschein, G. R., Paulus, R., Curran, W. J., Robert, F., Fossella, F., Werner-Wasik, M., Herbst, R. S., Doescher, P. O., Choy, H., & Komaki, R. (2011). Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 17, 2312-2318.
  4. Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2013). The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer treatment reviews, 4,558-566.
Source: Merck and Pfizer
Related Links:

Written by asiafreshnews

April 8, 2015 at 6:18 pm

Posted in Uncategorized

OneAsia Deploys Appcara’s App360 Appliance PRO for its Cloud Orchestrator

leave a comment »

-OneAsia’s Cloud Orchestrator accelerates enterprises’ application to the cloud

HONG KONG /PRNewswire/ — OneAsia, the leading IT services, cloud solutions and data centers services provider in Asia, today announced that it has deployed Appcara’s App360 Appliance PRO, the state-of-the-art multi-cloud and application automation solution, into OneAsia’s data centers to offer Cloud Orchestrator solutions across Asia .

Cloud Orchestrator is a cloud management system that allows enterprises to move applications into a virtualised infrastructure. Charles Lee, Founder & CEO of OneAsia said, “The Cloud Orchestrator, which is the key enabler for OneAsia’s latest offer OneCloud, seamlessly extends the traditional onsite IT infrastructure into the cloud. This allows enterprises to rapidly deploy, efficiently manage and simplify the migration of applications into the cloud. This is a guaranteed end-to-end service to our customers.” Cloud Orchestrator’s end-to-end cloud management offers standardised provisioning, on-going support and maintenance and application migration for businesses.

The key advantages of OneAsia’s Cloud Orchestrator include:

  • Speedup virtualised infrastructure for server connectivity, VM, OS and Apps
  • Standardised user and administration experience
  • Carrier neutral connectivity
  • Cloud and Hypervisor Neutral
  • Centralised patch management at all layers

With OneAsia’s trans-Pacific networks, world-class data centers and cloud services, OneAsia’s Cloud Orchestrator offers enterprises tremendous flexibility and simplicity in migrating the business critical application workloads into the cloud.

OneAsia will have a physical presence to demonstrate Cloud Orchestrator at the upcoming Intel Developer Forum (IDF) 2015 on 8-9 April, 2015. The booth will be located at booth #716 at the Sheraton Futian Shenzhen (Fuhua Rd, Futian District Shenzhen, Guangdong 518048).

About OneAsia

OneAsia offers a full range of cloud computing solutions and data centre services, from infrastructure, platform to application software, aiming to help clients to manage its IT budget and resources effectively in meeting core business needs. OneAsia’s top-tier rated data centres are located across Asia to keep its customers connected from anywhere in the world with consistent levels of quality, security and services. OneAsia is at the forefront of the industry with extensive infrastructure coverage in Greater China, Singapore, Malaysia and Vietnam.

For more information, please visit www.oneAs1a.com

For media enquiry, please contact:
Maggie Sun
Email: maggiesun@oneas1a.com
Tel: +852 3979 3900

Source: OneAsia Network Limited
Related Links:

Written by asiafreshnews

April 8, 2015 at 6:07 pm

Posted in Uncategorized

At NAB 2015 Mobile Viewpoint Launches WebStreamur, a Global Marketplace for Live Mobile Journalism

leave a comment »

ALKMAAR, the Netherlands, April 7, 2015 /PRNewswire/ — Mobile Viewpoint announces the launch of WebStreamur, a new platform which delivers high quality live video from any place to the web. WebStreamur utilizes the award winning bonding technology of Mobile Viewpoint to live stream from any location using bonded IP channels. During NAB 2015 WebStreamur will launch its own range of products including an App for MacBook, iPhone and Android and 3 dedicated appliances. WebStreamur utilizes YouTube to deliver live streams via WebStreamur channels on any device and create revenues based on sponsoring. WebStreamur utilizes Twitter for announcements and instant feedback. WebStreamer can be used for any event but will focus on the delivery of college sports content around the world. WebStreamur wireless bonded video transmitters and app’s will unleash the potential of unique sports events no matter where and when they take place.

(Logo: http://photos.prnewswire.com/prnh/20150407/738861)

Mobile Viewpoint CEO Michel Bais:

“Since the beginning of Mobile Viewpoint we looked into the broadcast of smaller but attractive sport events on the Internet. The growing popularity of watching video online via streaming platforms like YouTube, LiveStream, Meerkat and Periscope opens a marketplace for the delivery of live sports and other events that do not have the reach to get on normal Broadcast Television. This makes it, in combination with our unique bonding technology, possible to deliver a high quality end-to-end solution and distinguishes WebStreamur from other #mojo products. WebStreamur gives the smaller content producers and sport teams easy access to a bigger audience and a global marketplace to monetize their content.”

On Mobile Viewpoint

Mobile Viewpoint is a global player, focusing on the development and implementation of solutions for both the broadcast and security industries. Based on their H.264 and H.265 codec implementations, combined with patented technology, allowing for HD video to be transmitted over bonded IP connections. Customers include major broadcasters, such as BBC, Al-Arabiya, Sky Sports News, NBC Sports.

Meet Mobile Viewpoint and Webstreamur at NAB 2015 Central Hall, stand 2807
http://www.mobileviewpoint.com / http://www.webstreamur.com

Source: Mobile Viewpoint

Written by asiafreshnews

April 8, 2015 at 5:51 pm

Posted in Uncategorized

RS Components Boosts Industrial Interconnections Portfolio with HARTING Han(R) Ex Connectors for Intrinsically Safe Circuits

leave a comment »

-High-quality connectors specified for use in explosive environments deliver enhanced flexibility, reliability, and ease of use

HONG KONG /PRNewswire/ — RS Components (RS), the trading brand of Electrocomponents plc (LSE:ECM), the global distributor for engineers, has extended its range of interconnection solutions serving industries such as mining, chemicals, process automation, and oil and gas, with the addition of HARTING Han® Ex connectors for use in potentially explosive environments.

RS Components boosts industrial interconnections portfolio with HARTING Han® Ex connectors for intrinsically safe circuits
RS Components boosts industrial interconnections portfolio with HARTING Han® Ex connectors for intrinsically safe circuits

Han Ex connectors meet the intrinsic safety requirements of CENELEC equipment codes ia, ib and ic, allowing use in explosion zones 0, 1 and 2[1], zones 1 and 2, or zone 2 respectively. The connectors comply with DIN EN 60 079-0 and DIN EN 60 079-11 standards, and are T6 temperature classified for use where ignition hazard exists at temperatures as low as 85 degrees Celsius.

The Han Ex connector range comprises a set of hoods, housings and inserts designed as a system to satisfy intrinsically safe applications. HARTING’s patented vibration-proof Han-Quick Lock® termination technology allows fast and easy assembly without special tools. Alternatively, crimp terminations are available, which can be used with wire gauges down to AWG 26. The inserts have greater than 10 Gigaohm insulation resistance, and housings are powder coated in the standard blue colour used to indicate an intrinsically safe circuit.

All the connectors ensure IP65 ingress protection when mated, and are specified for operation in ambient temperatures from -20 degrees celsius to 40 degrees Celsius. The full Han Ex range, comprising variants with 4, 7, 8, or 12 contacts, is available now from RS Components. For further information, and to order Han Ex connectors, visit the website at www.rs-online.com.

[1] 

Zones 0, 1, 2: CENELEC/IEC-defined zones in which an explosive gas/air mixture is continuously present for long periods (zone 0), or likely to occur in normal operation (zone 2), or not likely to occur in normal operation (zone 3)

About RS Components

RS Components and Allied Electronics are the trading brands of Electrocomponents plc, the global distributor for engineers. With operations in 32 countries, we offer around 500,000 products through the internet, catalogues and at trade counters to over one million customers, shipping more than 44,000 parcels a day. Our products, sourced from 2,500 leading suppliers, include semiconductors, interconnect, passives and electromechanical, automation and control, electrical, test and measurement, tools and consumables.

Electrocomponents is listed on the London Stock Exchange and in the last financial year ended 31 March 2014had revenues of GBP1.27bn.

For more information, please visit the website at www.rs-online.com.

RS Components
Tan Soo Chun
Public Relations Manager – Asia Pacific
Email: soochun.tan@rs-components.com
Telephone: +65-6391-5745

Edelman Public Relations (Singapore)
Yvette Yeo
Manager
Email: yvette.yeo@edelman.com
Telephone: +65-6347-2355

Further information is available via these links:
@RSElectronics; @alliedelec; @designsparkRS

RS Components on Linkedin
http://www.linkedin.com/company/rs-components

RS Components on Weibo
http://e.weibo.com/u/3206377000?type=0

Relevant Links:

Electrocomponents plc
www.electrocomponents.com

RS Components
www.rs-online.com/

DesignSpark
www.designspark.com

Photo – http://photos.prnasia.com/prnh/20150326/8521501942
Logo – http://www.prnasia.com/sa/2011/05/04/20110504368830.jpg

Source: RS Components Singapore

Related stocks: LSE:ECM OTC-PINK:EENEY

Written by asiafreshnews

April 8, 2015 at 5:12 pm

Posted in Uncategorized

Aptuit To Expand API Capacity Due To Increased Demand For Integrated Development

leave a comment »

— Opens 1600L/1000L reactor stream at Oxford, UK and increases API capacity at Verona, Italy

GREENWICH, Conn.,/PRNewswire/ — Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit has increased its global capacity for Active Pharmaceutical Ingredient (API) Manufacture due to increased demand for API, and for its integrated and comprehensive candidate-to-IND development solution.

Dr. Goldman stated, “Customer demand for our high quality, integrated, fully inclusive candidate-to-IND solutions has increased over 300% on an annual basis. As part of our strategy of investing in our infrastructure, we therefore have opened a 1600L/1000L reactor stream at our internationally renowned API facility in Oxford, UKand increased throughput at our 400L reactors at our world-class, fully integrated, former large Pharma R&D center of excellence in Verona, Italy.

Dr. Goldman explained that Aptuit’s strategy will allow increased throughput of integrated development programs, as well as deliver standalone API at 40-120 kg batch scale for early to mid-stage clinical trials. “There is a gap in the market for high quality API at this scale, and Aptuit is delighted to serve this need.”

“As recognized by our recent 2015 Life Science Leader CMO Leadership Award for Quality, our company differentiates in API by quality, best-in-class science, and delivery of complex chemistry solutions. Our ability to combine this with drug product and analytical services results in unique integrated offerings in both CMC and complete IND enabling solutions. The innovative approach has created strong demand amongst customers, and stimulated our plan to re-invest to increase our capacity in API.

Dr. Goldman concluded, “Our mission is to help discover and develop new medicines with outstanding quality and world class scientific problem solving. Aptuit is committed to being the best-in-class provider of fully integrated drug discovery and development services, supported by a culture of scientific excellence and innovation.”

Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development center in Verona, Italy. The company maintains resources around the world, with facilities in the US, UK and Italy. Aptuit LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world’s leading private equity investors.

For more information about Aptuit, visit www.aptuit.com

CONTACT: Nerina Coppini, nerina.coppini@aptuit.com

Source: Aptuit
Related Links:

Written by asiafreshnews

April 8, 2015 at 5:09 pm

Posted in Uncategorized

AMRI to Close Holywell, U.K. API Manufacturing Facility

leave a comment »

ALBANY, N.Y.,/PRNewswire/ — AMRI (NASDAQ: AMRI) announced today that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredients (API) and intermediates.

“This was a difficult decision as it impacts team members who have made valuable contributions to AMRI,” saidWilliam S. Marth, AMRI President and Chief Executive Officer. “We will work diligently to ensure the closing of the Holywell facility goes as smoothly as possible for our customers and employees.”

AMRI will transition activities at the Holywell site to other facilities within the AMRI network and plans to cease operations at the site by the end of 2015. Closure of the site is expected to affect approximately 62 positions.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website atwww.amriglobal.com or follow us on Twitter (@amriglobal).

About AMRI API Manufacturing
With demonstrated success in large scale API Manufacturing, we offer the preeminence and scale to support the chemical development and cGMP manufacture of complex Active Pharmaceutical Ingredients (API). Our global manufacturing footprint, which also includes manufacturing in Europe and India, provides customers with access to global markets and low-cost manufacturing of APIs or intermediates. In addition, we have the skills and infrastructure to adequately provide complex API research and development, analytical support and support with global regulatory activities.

Source: AMRI

Related stocks: Frankfurt:AYM NASDAQ-NMS:AMRI

Written by asiafreshnews

April 8, 2015 at 5:06 pm

Posted in Uncategorized

WatchGuard Technologies Named to JMP Securities’ Fast 50 List of Hottest Privately Held Security and Networking Companies

leave a comment »

— Report highlights WatchGuard’s modular platform approach, ability to continually innovate to keep up-to-date with ever-changing threat landscape
— Recognition moves WatchGuard into position as one of industry’s most awarded network security companies

SEATTLE, /PRNewswire/ — WatchGuard Technologies, a global leader in multi-function security appliances, today announced it has been named to the JMP Securities Fast 50 list of hottest privately held security and networking companies. The list, which was created by the Internet security and communications infrastructure team at JMP, recognizes innovators that have the capability to dominate their respective markets.

Logo – http://photos.prnewswire.com/prnh/20140224/SF69246LOGO

“In just over 12 months, WatchGuard has delivered a continual cadence of innovations that are raising the bar for the network security industry, and it’s terrific to have this recognition from JMP Securities for the value they see us bringing to the market for our customers,” said Rich Barber, chief financial officer at WatchGuard Technologies. Following are the highlights of the company’s most recent introductions:

  1. WatchGuard Firebox® M440 – This Next Generation Firewall (NGFW) or Unified Threat Management (UTM) appliance features truly independent ports, which dramatically simplifies network segmentation and ensures accurate policy creation.
  2. WatchGuard Firebox M400 and M500 – These NGFW or UTM firewalls vault past the competition by inspecting encrypted traffic 149 percent faster than competitors and up to 61 percent faster with all services enabled, allowing them to keep pace with explosive market growth in network and encrypted Internet traffic.
  3. APT Blocker – This advanced malware protection solution delivers real-time protection against advanced threats in minutes not hours.
  4. Dimension Policy Map – This feature for WatchGuard’s real-time visibility solution gives IT professionals X-ray vision into firewall configurations and network traffic so they can see the flow and impact of policies across the entire network in real-time.
  5. WatchGuard Firebox T10 – This enterprise-level UTM appliance designed for the home and small office, allows enterprises to protect their high-value home based employees at the same level they protect their corporate networks.

In the past year, highlights of other awards and recognition WatchGuard has received include PC Magazine Highly Recommended, Firebox T10; APT Security solution of the Year, Computing Security Awards; Network Security Company of the Year, Network Computing Magazine; Security Product of the Year, Firebox M440, Network Computing Magazine; and the Top-Rated Next Generation Firewall, WatchGuard XTM 1525, NSS Labs.  For a full list to the company’s recent awards, click here.

About WatchGuard Technologies, Inc.

WatchGuard® Technologies, Inc. is a global leader of integrated, multi-function business security solutions that intelligently combine industry standard hardware, best-of-breed security features, and policy-based management tools. WatchGuard provides easy-to-use, but enterprise-powerful protection to hundreds of thousands of businesses worldwide. WatchGuard products are backed by WatchGuard LiveSecurity® Service, an innovative support program. WatchGuard is headquartered in Seattle, Wash. with offices throughout North America, Europe,Asia Pacific, and Latin America. To learn more, visit WatchGuard.com.

For additional information, promotions and updates, follow WatchGuard on Twitter @WatchGuardTech on Facebook, or on the LinkedIn Company page.

WatchGuard is a registered trademark of WatchGuard Technologies, Inc. All other marks are property of their respective owners.

Contacts:
Kerry Desberg
WatchGuard Technologies
+1-206-613-3760
Kerry.Desberg@watchguard.com

Justin Hall
Voxus PR
+1-253-444-5442
jhall@voxuspr.com

Source: WatchGuard Technologies, Inc.

Written by asiafreshnews

April 8, 2015 at 4:57 pm

Posted in Uncategorized

Pocomoke City Goes Solar With 2.1 Megawatt System From SunEdison

leave a comment »

BELMONT, Calif., April 2, 2015 /PRNewswire/ — SunEdison, Inc. (NYSE:SUNE), the world’s largest renewable energy development company, today announced the completion of a 2.1 megawatt solar energy system that will supply electricity to Pocomoke City’s wastewater treatment plant via a 20 year power purchase agreement. These projects were on the TerraForm Power call right list and have been acquired and are now owned by TerraForm Power, Inc. (Nasdaq: TERP), a global owner and operator of clean energy power plants.

Logo – http://photos.prnewswire.com/prnh/20150203/173064LOGO

The Pocomoke City solar system is designed to produce more energy than the on-site facility needed. Under aggregated net metering, other buildings owned by Pocomoke City can share the output of these solar systems, even if they are not physically connected to them or are on a different meter.

“Aggregated net metering is an innovative way for nonprofits, farms, and municipalities to maximize electricity savings and meet their carbon reduction goals with minimal capital up-front,” said Michael Volpe, Sales Director at SunEdison. “We’re proud to be working with Standard Solar, our development and EPC partner, on these opportunities.”

“Pocomoke City calls itself The Friendliest Town on the Eastern Shore, and, thanks to the foresight of city officials, it is well on its way to being known as the Greenest Town on the Eastern Shore,” said Tony Clifford, Chief Executive Officer of Standard Solar. “With no financial outlay required by Pocomoke City, sizeable savings in electricity costs, and positive contributions to its citizens’ environmental future, more and more municipalities are seeing the short- and long-term advantages of going solar.”

“Our appreciation goes out to SunEdison and Standard Solar, who introduced us to this innovative solution,” said Russell Blake, City Manager for Pocomoke City. “We’re using aggregated net metering to maximize savings on our electric bill.”

This project was made possible through Maryland’s Aggregated Net Metering Program, which is available for municipal institutions, agriculture and non-profits. Through its Renewable Portfolio Standard, the State of Maryland hopes to generate 20 percent of its electricity from renewable sources by 2020.

About SunEdison
SunEdison is the world’s largest renewable energy development company and is transforming the way energy is generated, distributed, and owned around the globe. The company manufactures solar technology and develops, finances, installs, owns and operates wind and solar power plants, delivering predictably priced electricity to its residential, commercial, government and utility customers. SunEdison is one of the world’s largest renewable energy asset managers and provides asset management, operations and maintenance, monitoring and reporting services for its renewable energy customers around the world. Corporate headquarters are in the United States, with additional offices around the world. SunEdison’s common stock is listed on the New York Stock Exchange under the symbol “SUNE.” To learn more visit http://www.sunedison.com.

About TerraForm Power
TerraForm Power is a renewable energy leader that is changing how energy is generated, distributed and owned. TerraForm Power creates value for its investors by owning and operating renewable energy power plants. For more information about TerraForm Power, please visit http://www.terraform.com.

About Standard Solar
Standard Solar, Inc. is a leader in the full-service development, construction, integration, financing and installation of solar electric systems. Dedicated to making Distributed Generation (“DG”) solar solutions more accessible, the company is leading the way to energy independence. The company is committed to offering responsible and energy cost-saving solar solutions that conform to the highest standards. Since 2004, Standard Solar has been developing solar projects to creatively solve the energy needs of commercial, industrial, educational, government, utility and other clients. Named one of the Fastest Growing Private Companies in America for four consecutive years by Inc. Magazine, Standard Solar operates nationally and is headquartered in Rockville, MD. For more information, please visit http://www.standardsolar.com.

Forward-Looking Statements
Certain matters discussed in this press release are forward-looking statements, including: that the 2.1 megawatt solar PV system for Pocomoke City will benefit all its facilities; and that the municipality is purchasing the energy via a 20-year power purchase agreement (PPA) with SunEdison. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Potential risks and uncertainties include changes in applicable regulatory requirements and incentives for production of solar power; and general business and economic conditions, including seasonality of the industry, and other risks described in SunEdison’s filings with the United States Securities and Exchange Commission. These forward-looking statements represent SunEdison’s judgment as of the date of this press release. SunEdison disclaims, however, any intent or obligation to update these forward-looking statements.

Source: SunEdison, Inc.

Written by asiafreshnews

April 8, 2015 at 4:56 pm

Posted in Uncategorized

An Unlikely Collaboration – Fragrance Du Bois teams up with Arabic singer to create ‘Life’s Treasure’ A Song for Oud

leave a comment »

SINGAPORE /PRNewswire/ — In what must surely be a world’s first, Fragrance Du Bois (a French perfume house and retailer specialising in the use of sustainable Oud), and Nadeem Nour (one of the Middle East’s best known and most respected singer/songwriters), came together to produce a musical enterprise close to both their hearts.

Nadeem Nour is a well-renowned Jordanian singer. The reason for his artistic name "Nadeem Nour" is that it is said that from the first moment you hear him, you can feel the light in his voice
Nadeem Nour is a well-renowned Jordanian singer. The reason for his artistic name “Nadeem Nour” is that it is said that from the first moment you hear him, you can feel the light in his voice

“About a year ago I was introduced by a friend to a gentleman from Iran who had just returned from visitingThailand and Malaysia. While he was there, he discovered the agarwood (Oud) plantations owned and managed by Asia Plantation Capital,” said Nadeem Nour in Dubai recently. “I became fascinated when I learned that not only was much of the Oud that we take for granted coming from illegal sources — not only in the past, but also today — but that it was in danger of extinction in the wild as a result.”

“Having grown up in Jordan, with Oud being very much a part of my daily life, and that of my family, I felt guilty when I realised that like many others, I could have spent my entire life taking Oud for granted, without ever wondering where it actually came from. The thought that I may actually be part of driving an illegal industry was horrifying.”

Nadeem continued, “I became deeply concerned, and as I feel passionately for the world in which we live, I decided to do my own research and find out the facts. I quickly realised — after talking to friends, and doing some research on the internet and looking at several news reports — that we had reached a situation where Oud, in the wild, was soon to be no more. I also realised that I was not alone in my ignorance. Hardly any of my friends were aware of Oud in terms of where it came from, and the threats it faces. Like me, they pretty much took it for granted.”

Nadeem went on to detail how important Oud was in Arabic culture and heritage, further lamenting the fact that the source was often unreliable. International fashion houses and perfume brands are now putting Oud into their products in increasing amounts, creating pressure on future supplies of the mystical substance.

Agarwood, and Oud (the oil derived therefrom), is now on the CITES (the Convention on International Trade in Endangered Species of Wild Flora and Fauna), list of endangered species, and as such, all trade has to be legal, certified, and sustainable. Demand is huge, far outstripping supply, and only sustainable plantations are the way forward.

“Asia Plantation Capital and their sister company Fragrance Du Bois,” continued Nadeem, “are two companies leading the way in making this industry transparent and sustainable for the benefit of all users of Oud – not only in the Gulf region, but also across the world. I decided that this story had to be told, and for me the only way to tell the story was through traditional Arabic words and music.”

Nadeem Nour has been a rising star on the Middle Eastern music scene for several years since appearing in the Jordanian Pop Idol show, and has built up a loyal following for his beautiful singing voice, heartfelt lyrics, and the music he performs across the Gulf. Dubbed ‘Nadeem Nour’ by Tarek Al Arians, the artist has evolved to the point at which listeners can feel the ‘light in his voice’, from the first moment you hear him sing.

Fragrance Du Bois, Asia Plantation Capital and Nadeem Nour earnestly hope that the light in his voice helps to tell a story that we all need to hear, and that ‘Life’s Treasure’ imparts a vital message when it comes to protecting a species that could all too easily have been lost forever.

A video of the song can be watched here http://youtu.be/PsV0Ku4vWDU

About Fragrance Du Bois

Fragrance Du Bois is a niche luxury perfume house working closely with sustainable plantations in Asia, bringing exciting new 100% organic Oud oil based fragrances to exclusive markets worldwide. Sustainably sourcing the finest raw materials across the globe, working with French perfumers to create a full range of products, and also providing bespoke fragrance services, Fragrance Du Bois is personal luxury with a conscience. With exclusive fragrance lounges around the world, in Dubai, Hong Kong, Thailand, Malaysia and Singapore, Fragrance Du Bois creates only the finest experience in bespoke perfumery.

Fragrance Du Bois is known as Parfums Du Bois in France and in non-French speaking markets, as Fragrance Du Bois.

About Asia Plantation Capital

Quick facts:

  • US$ 600 million – combined value of assets owned and under management
  • US$ 53.5 million – turnover in the last financial year
  • US$ 100 million – turnover forecast for current financial year
  • 2,000,000 – Aquilaria trees today, on Agarwood plantations.

Asia Plantation Capital (APC) is the owner and operator of a diverse range of commercial plantation and farming businesses across the Asia-Pacific region and around the world, and is part of the Asia Plantation Capital Group of associated companies. Its focus is on multicultural and diverse plantation projects geared to the domestic and commercial demands of the countries in which it operates. Working closely with, and supporting local communities, is an underlying core principle of the APC business, providing social and cultural support, as well as investment, to move these communities away from deforestation and illegal logging activities, previously seen as a main source of income in some regions of Asia. Established officially in 2008 (although operating privately since 2002) the group now has plantation and agricultural projects on four continents, with operational projects at various stages in Thailand, Malaysia, China, Laos, India, Cambodia, Sri Lanka, Myanmar, Vietnam, North America and Europe.

Promoting the use of sustainable and certified wood is the best way of preventing deforestation, protecting biodiversity, and combatting poverty in the tropical rainforest regions. For the yachting sector (a major user of teak) which strives for excellence and which is already involved in environmental efforts, this is also a way of ensuring that no wood from illegal logging is used.

CONTACT: Stéphanie du Ché, PR & Media Manager Europe, stephanie.duche@asiaplantationcapital.com, +33 616 361 108; Adrian Heng, Group Marketing Director, adrian.heng@asiaplantationcapital.com, +65 6299 1778

Photo – http://photos.prnasia.com/prnh/20150403/8521502133

Source: Asia Plantation Capital

Written by asiafreshnews

April 8, 2015 at 4:54 pm

Posted in Uncategorized

Sentinel Studies Find New Microcurrent Generating Wound Dressing Effective in Disrupting Bacterial Biofilms

leave a comment »

TEMPE, Ariz.,/PRNewswire/ — Procellera® from Vomaris Innovations, Inc. (now available through Arthrex as JumpStart™) – the only wound dressing powered by Advanced Microcurrent Technology™, has been found to significantly disrupt bacterial biofilms, according to two new published research studies in PLoS ONE and the Journal of Wound Care1-2.

Studies conducted at The Ohio State University (OSU) Wexner Medical Center, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and its Diagnostics and Translational Research Center (DTRC) both confirmed significant anti-biofilm efficacy of Procellera Technology. Bacterial biofilms are complex networks of microorganisms bound together and covered with a slimy protective barrier. They can be found in living tissues, indwelling medical devices, and implants. Biofilm-associated bacteria are extremely resistant to antibiotics and have been implicated in wound infections, resulting in delayed healing, poor clinical outcomes and significant healthcare costs.

In the OSU study, researchers evaluated the effects of Procellera / JumpStart technology to better understand its antimicrobial properties, particularly related to the disruption of Pseudomonas aeruginosa. This bacterial species is often present in chronic wound infections and readily forms biofilm, making it extremely difficult to treat effectively with available antibiotics.

“This work presents clear evidence that this wireless electroceutical dressing disrupts bacterial biofilm,” said Chandan K Sen, Ph.D., Professor of Surgery and Director of the Comprehensive Wound Center at OSU Wexner Medical Center. “Our findings introduce the option of a new affordable technology platform to fight chronic wound infection in which bacterial biofilms are abundant.”

Several mechanisms behind the ability of this Advanced Microcurrent Technology to disrupt the formation of bacterial biofilms were identified:

  • First, the microcurrent technology aided the generation of superoxide radicals, chemical compounds that are produced by white blood cells in the body with the goal to fight infection.
  • Second, researchers discovered that the microcurrents significantly impaired the activity of glycerol-3-phosphate dehydrogenase (GPDH), an electrically sensitive enzyme that is required for bacterial respiration and metabolism.
  • Finally, the research found that the microcurrents disrupted some key antimicrobial resistance genes, silenced some key redox-sensitive, quorum sensing genes and interfered with production of bacteria signaling molecules, thus preventing the bacteria from forming the complex networks that make up biofilms.

Because bacterial biofilms are known to compromise production of antimicrobial superoxide radicals by immune cells, weakening the ability of the body to fight infection, the study’s observation that Procellera initiated spontaneous generation of superoxide radicals is particularly significant.

Research performed at DTRC and HJF studied the anti-biofilm properties of Procellera Technology against ten clinical wound pathogens in a poloxamer biofilm model customized to evaluate the bioelectric dressing. Investigators demonstrated Procellera / JumpStart’s effectiveness against biofilms across multiple species of clinical wound pathogens, with up to a thousand-fold inhibition of microbial growth in several species when compared to controls. This observation is consistent with the observations reported independently from OSU.

“We are very encouraged by the implications of these results for wound care, which showed that this electroceutical dressing was effective in inhibiting growth of both mono- and multi-species biofilms, including multi-drug resistant strains,” said Dr. Mina Izadjoo, principal investigator for the DTRC/HJF study.

“Bacterial biofilms can dramatically impede wound healing and penetrate deeper into a wound bed to further infect implanted devices,” said Michael Nagel, President and Chief Executive Officer of Vomaris Innovations, Inc. “Because of their resistance to treatment, biofilms present a significant challenge in today’s healthcare environment. We, at Vomaris, are extremely pleased by these latest findings by two independent laboratories about this Technology’s ability to inhibit and disrupt biofilms and the significant implications this has for infection control and wound healing.”

PLoS One study co-authors included Jaideep Banerjee, Piya Das Ghatak, Sashwati Roy, Ph.D., Savita Khanna, Ph.D., Craig Hemann, Jay L Zweier, M.D., and Daniel Wozniak, Ph.D. of The Ohio State University. The study was supported in part by the National Institutes of Health: Grant Numbers GM077185, GM069589 and DOD W81XWH-11-2-0142 to CKS; NIH NR013898 to CKS and DJW; and in part by NIH DK076566 to SR and NIH R01AI097511 to DJW.

Co-authors of the Journal of Wound Care article included Hosan Kim, Ph.D. The study was supported by Vomaris.

About Vomaris Innovations
Vomaris Innovations, Inc. is an electroceutical company specializing in microcurrent-generating solutions for the wound care market and beyond. Utilizing electricity to mimic the body’s own physiologic electric currents, which are essential for skin repair and wound healing, Vomaris’ core technology platform employs imbedded microcell batteries that generate microcurrents in the presence of a conductive medium to harness the power of electricity to support healing.

Vomaris’ flagship product, Procellera® Antimicrobial Wound Dressing is the only wound dressing in the world powered by Advanced Microcurrent Technology. It is a new generation solution for wound and incisional care with demonstrated broad-spectrum antimicrobial efficacy3 and the ability to promote wound healing4, and is available exclusively through Arthrex as JumpStart Technology with Advanced Microcurrent Healing.

Procellera / JumpStart is currently used in multiple acute and chronic wound care settings, including clinical, animal and consumer health. The company’s ongoing mission is to develop and deliver evidence-based, patient-focused and cost-effective solutions, backed by a commitment to quality and innovation for the improvement of lives.

About Arthrex
Arthrex, Inc. is a global medical device company and leader in new product development and medical education in orthopaedics. With a corporate mission of helping surgeons treat their patients better, Arthrex has pioneered the field of arthroscopy and developed more than 8,500 innovative products and surgical procedures to advance minimally invasive orthopaedics worldwide. Arthrex remains dedicated to delivering uncompromising quality to the healthcare professionals who use its products, and ultimately, the millions of patients whose lives these products impact.

  1. Kim H, Izadjoo MJ. Antibiofilm efficacy evaluation of a bioelectric dressing in mono- and multi-species biofilms. J Wound Care 2015; 24 Suppl 2:S10-4.
  2. Banerjee J, Ghatak PD, Roy S, Khanna S, Hemann C, Deng B, et al. (2015) Silver-Zinc Redox-Coupled Electroceutical Wound Dressing Disrupts Bacterial Biofilm. PLoS ONE 10(3): e0119531. doi:10.1371/journal.pone.0119531
  3. Kim H, Makin I, Skiba J, Ho A, Housler G, Stojadinovic A, Izadjoo M. Antibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Pathogens.  The Open Microbiology Journal 2014; 8:15-21.
  4. Banerjee J, Ghatak P, Roy S, Khanna S, Sequin EK, Bellman K, Dickinson BC, Suri P, Subramaniam V, Chang CJ, Sen CK.  Improvement of human keratinocyte migration by a redox active bioelectric dressing. PLOS ONE. 2014; 9(3).
Source: Vomaris Innovations, Inc.

Written by asiafreshnews

April 8, 2015 at 4:50 pm

Posted in Uncategorized